Litian Zhou, Jiajia Xu, Jian Hu, Jiao Lei, Pinglai Yang
Purpose: To determine the anesthetic effect and related indicators following concurrent administration of remifentanil and propofol in cerebral hemorrhage surgery patients.Methods: A total of 88 cerebral hemorrhage patients admitted in Lishui People’s District Hospital, Nanjing, China, from December 2019 to December 2020, were assigned to two groups, viz, control group which received fentanyl and propofol for anesthesia, while study group was administered remientanil combined with propofol for anesthesia There were 44 patients in each group. Hemodynamic index, brain injury marker index, stress response index, awakening condition, propofol dosage, anesthetic effect, and adverse reactions were assessed and recorded.Results: Heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) at T2 and T3 of the two groups were less than those at T1. At T3, the study group’s HR, DBP, and SBP were substantially higher than those of control group (p < 0.05); At 12 and 24 h after operation, brain injury markers and stress response indices in study group were significantly lower compared to control group (p < 0.05), while in comparison to control group (79.55 %), the degree of anesthesia in the study group was higher (95.45 %; p < 0.05). The incidence of adverse reactions in the study group (15.91 %) was lower than in control group (43.18 %; p < 0.05).Conclusion: Remifentanil, when combined with propofol anesthesia, stabilizes hemodynamics, protects against brain injury, and reduces stress reactions in patients undergoing cerebral hemorrhage surgery. The combination is also highly effective and safe. However, validation of these findings in larger clinical trials is required.
{"title":"Effect of remifentanil co-administered with propofol on stress response and postoperative complications in patients with cerebral hemorrhage undergoing surgical anesthesia","authors":"Litian Zhou, Jiajia Xu, Jian Hu, Jiao Lei, Pinglai Yang","doi":"10.4314/tjpr.v22i8.27","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.27","url":null,"abstract":"Purpose: To determine the anesthetic effect and related indicators following concurrent administration of remifentanil and propofol in cerebral hemorrhage surgery patients.Methods: A total of 88 cerebral hemorrhage patients admitted in Lishui People’s District Hospital, Nanjing, China, from December 2019 to December 2020, were assigned to two groups, viz, control group which received fentanyl and propofol for anesthesia, while study group was administered remientanil combined with propofol for anesthesia There were 44 patients in each group. Hemodynamic index, brain injury marker index, stress response index, awakening condition, propofol dosage, anesthetic effect, and adverse reactions were assessed and recorded.Results: Heart rate (HR), diastolic blood pressure (DBP), and systolic blood pressure (SBP) at T2 and T3 of the two groups were less than those at T1. At T3, the study group’s HR, DBP, and SBP were substantially higher than those of control group (p < 0.05); At 12 and 24 h after operation, brain injury markers and stress response indices in study group were significantly lower compared to control group (p < 0.05), while in comparison to control group (79.55 %), the degree of anesthesia in the study group was higher (95.45 %; p < 0.05). The incidence of adverse reactions in the study group (15.91 %) was lower than in control group (43.18 %; p < 0.05).Conclusion: Remifentanil, when combined with propofol anesthesia, stabilizes hemodynamics, protects against brain injury, and reduces stress reactions in patients undergoing cerebral hemorrhage surgery. The combination is also highly effective and safe. However, validation of these findings in larger clinical trials is required.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the interaction between parecoxib and p38MAPK under simulated physiological conditions.Methods: The interaction between parecoxib and p38MAPK was studied under simulated physiological conditions using spectroscopy-based methods. The effect of parecoxib on the microenvironment and conformation of p38MAPK chromophore was studied by synchronous fluorescence spectroscopy, three-dimensional fluorescence, time-resolved fluorescence spectroscopy, circular dichroism spectroscopy, and ultraviolet-visible absorption spectroscopy.Results: Synchronous fluorescence spectroscopy showed that addition of parecoxib changed the structure of p38MAPK and destroyed the original stable structure. Three-dimensional fluorescence spectroscopy showed that the hydrophilicity of the microenvironment in which the fluorescent chromophore is located was enhanced, and the polarity increased such that the serum protein macromolecules tend to be unfolded, and the alpha-helix content reduced. Time-resolved fluorescence spectroscopy showed that the presence of parecoxib hardly affected the fluorescence quenching of p38MAPK, and the combination of parecoxib and p38MAPK forms a stable complex (static quenching). Circular dichroism spectroscopy revealed the combined parecoxib change, the secondary structure of p38MAPK and reduced the alpha-helix content. Ultraviolet-visible absorption spectroscopy revealed changes in the microenvironment of the three amino acid residues as well as the tertiary structure of the protein.Conclusion: The results shows that parecoxib has a significant effect on the structure of p38MAPK. In addition to explicitly inhibiting COX-2 and blocking arachidonic acid synthesis of prostaglandins, it inhibits the pathway involved in p38MAPK.
{"title":"Studies on <i>in vitro</i> binding of parecoxib to p38MAPK using spectroscopic methods","authors":"Xuejie Li, Kun Huang, Shan Zhong","doi":"10.4314/tjpr.v22i8.16","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.16","url":null,"abstract":"Purpose: To investigate the interaction between parecoxib and p38MAPK under simulated physiological conditions.Methods: The interaction between parecoxib and p38MAPK was studied under simulated physiological conditions using spectroscopy-based methods. The effect of parecoxib on the microenvironment and conformation of p38MAPK chromophore was studied by synchronous fluorescence spectroscopy, three-dimensional fluorescence, time-resolved fluorescence spectroscopy, circular dichroism spectroscopy, and ultraviolet-visible absorption spectroscopy.Results: Synchronous fluorescence spectroscopy showed that addition of parecoxib changed the structure of p38MAPK and destroyed the original stable structure. Three-dimensional fluorescence spectroscopy showed that the hydrophilicity of the microenvironment in which the fluorescent chromophore is located was enhanced, and the polarity increased such that the serum protein macromolecules tend to be unfolded, and the alpha-helix content reduced. Time-resolved fluorescence spectroscopy showed that the presence of parecoxib hardly affected the fluorescence quenching of p38MAPK, and the combination of parecoxib and p38MAPK forms a stable complex (static quenching). Circular dichroism spectroscopy revealed the combined parecoxib change, the secondary structure of p38MAPK and reduced the alpha-helix content. Ultraviolet-visible absorption spectroscopy revealed changes in the microenvironment of the three amino acid residues as well as the tertiary structure of the protein.Conclusion: The results shows that parecoxib has a significant effect on the structure of p38MAPK. In addition to explicitly inhibiting COX-2 and blocking arachidonic acid synthesis of prostaglandins, it inhibits the pathway involved in p38MAPK.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the role of nicotinamide phosphoribosyltransferase (NAMPT) in lipopolysaccharide (LPS)-induced damage in trophoblastic HTR-8/SVneo cells (HTR8 cells), with the aim of ultimately providing new therapeutic targets of preeclampsia (PE).Methods: Trophoblastic HTR-8/SVneo was cultured and treated with LPS to mimic PE in vitro, while FK866, an antagonist of NAMPT, was used to establish an inflammatory model of HTR8 cells. Western blot, enzyme-linked immunosorbent assay (ELISA) and quantitative real-time-polymerase chain reaction (qRT-PCR) were used to evaluate inflammatory response in HTR8 cells, and cell counting kit-8 (CCK8) and oxidative stress kits were performed to quantify cell activity in HTR cells.Results: Compared with the control group, the administration of LPS significantly increased the expression levels of NAMPT in HTR8 cells. FK866 suppressed the expression levels of proinflammatory factors IL-1β, TNF-α and IL-6, and alleviated inflammation by inhibiting NAMPT-mediated NF-κB pathway. The antioxidant effect of FK866 was achieved via activation of antioxidant proteins,catalase (CAT) and glutathione (GSH).Conclusion: FK866 protects HTR8 cells from LPS-induced inflammation and oxidative stress through the inhibition of NAMPT-NF-κB signaling pathway. Thus, NAMPT is a potential therapeutic target for preeclampsia (PE).
{"title":"Nicotinamide phosphoribosyltransferase inhibitor is a potential therapeutic target in LPS-induced human trophoblast cell injury","authors":"Zuoman Zhang, Lijun Tang, Meifang Huang, Guangliang Bi, Weimin Huang","doi":"10.4314/tjpr.v22i8.8","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.8","url":null,"abstract":"Purpose: To investigate the role of nicotinamide phosphoribosyltransferase (NAMPT) in lipopolysaccharide (LPS)-induced damage in trophoblastic HTR-8/SVneo cells (HTR8 cells), with the aim of ultimately providing new therapeutic targets of preeclampsia (PE).Methods: Trophoblastic HTR-8/SVneo was cultured and treated with LPS to mimic PE in vitro, while FK866, an antagonist of NAMPT, was used to establish an inflammatory model of HTR8 cells. Western blot, enzyme-linked immunosorbent assay (ELISA) and quantitative real-time-polymerase chain reaction (qRT-PCR) were used to evaluate inflammatory response in HTR8 cells, and cell counting kit-8 (CCK8) and oxidative stress kits were performed to quantify cell activity in HTR cells.Results: Compared with the control group, the administration of LPS significantly increased the expression levels of NAMPT in HTR8 cells. FK866 suppressed the expression levels of proinflammatory factors IL-1β, TNF-α and IL-6, and alleviated inflammation by inhibiting NAMPT-mediated NF-κB pathway. The antioxidant effect of FK866 was achieved via activation of antioxidant proteins,catalase (CAT) and glutathione (GSH).Conclusion: FK866 protects HTR8 cells from LPS-induced inflammation and oxidative stress through the inhibition of NAMPT-NF-κB signaling pathway. Thus, NAMPT is a potential therapeutic target for preeclampsia (PE).","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"2013 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To evaluate the effect of trimetazidine on ventricular remodeling and serum levels of cystatin C and endothelin-1 in patients with chronic heart failure (CHF).Methods: A total of 96 patients with CHF were randomly divided into two groups, given either conventional treatment (control group) or conventional treatment plus trimetazidine (study group) for 6 months. Clinical efficacy was compared between the two groups. Left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were measured using cardiac echocardiography before and after treatment. Patients wererecorded at 6 MVT before and after treatment. An automatic biochemical analyzer was used to assay serum Cys C levels before and after treatment. Serum levels of ET-1, galactose agglutinin-3 (GAL-3), brain natriuretic peptide (BNP) and heart natriuretic peptide (ANP) were determined by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Incidence of adverse events in CHF patients was compared between groups.Results: Study group had a significantly higher level of treatment effectiveness (91.67 %) and better improvement in left ventricular ejection fraction, left ventricular end-systolic diameter and left ventricular end-diastolic diameter than control group (p < 0.05). Serum levels of serum cystatin C, endothelin-1 and other biomarkers were also significantly lower (p < 0.05) in study group. Re-hospitalization rate was also lower in study group.Conclusion: Trimetazidine exerts a therapeutic effect on CHF patients, effectively improves cardiac function and reduces the rate of re-hospitalization.
{"title":"Effect of trimetazidine on ventricular remodeling, serum Cys C and ET-1 levels in patients with chronic heart failure","authors":"Xiaoyan Wu, Wenzhong Chen, Huiming Han","doi":"10.4314/tjpr.v22i8.24","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.24","url":null,"abstract":"Purpose: To evaluate the effect of trimetazidine on ventricular remodeling and serum levels of cystatin C and endothelin-1 in patients with chronic heart failure (CHF).Methods: A total of 96 patients with CHF were randomly divided into two groups, given either conventional treatment (control group) or conventional treatment plus trimetazidine (study group) for 6 months. Clinical efficacy was compared between the two groups. Left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD) were measured using cardiac echocardiography before and after treatment. Patients wererecorded at 6 MVT before and after treatment. An automatic biochemical analyzer was used to assay serum Cys C levels before and after treatment. Serum levels of ET-1, galactose agglutinin-3 (GAL-3), brain natriuretic peptide (BNP) and heart natriuretic peptide (ANP) were determined by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Incidence of adverse events in CHF patients was compared between groups.Results: Study group had a significantly higher level of treatment effectiveness (91.67 %) and better improvement in left ventricular ejection fraction, left ventricular end-systolic diameter and left ventricular end-diastolic diameter than control group (p < 0.05). Serum levels of serum cystatin C, endothelin-1 and other biomarkers were also significantly lower (p < 0.05) in study group. Re-hospitalization rate was also lower in study group.Conclusion: Trimetazidine exerts a therapeutic effect on CHF patients, effectively improves cardiac function and reduces the rate of re-hospitalization.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135353551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To determine the effect of sufentanil on myocardial apoptosis in rats with myocardial ischemia-reperfusion injury (MIRI).Methods: Fifty Sprague Dawley rats were randomly assigned to five groups: sham, model, low-dose, moderate-dose, and high-dose. The groups, except sham, underwent ligation of the left anterior descending coronary artery to establish the MIRI model. The low, moderate, and high-dose groups received intraperitoneal injections of sufentanil at different concentrations. Cardiac function, serum LDH, creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (MDA) content were evaluated. The mRNA expression levels of apoptosis genes and protein levels of p38 and p-p38 were assessed in myocardial tissues using various methods while apoptosis was assessed by TUNEL assay.Results: Compared to sham group, the model group exhibited significant decrease in fractional shortening (FS) and ejection fraction (EF), increase in CK activity, LDH, and MDA contents, lower SOD activity. Model group also showed increase in mRNA levels of B-cell lymphoma-2 (Bcl-2) and caspase- 3, higher apoptosis, significant increase in protein levels of p38 and p-p38, and higher level of myocardial apoptosis (p < 0.05). High-dose group demonstrated significant increase in FS and EF, decrease in LDH content and CK activity, lower MDA content, higher SOD activity, decrease in mRNA levels of Bcl-2 and caspase-3, lower apoptosis, decrease in protein levels of p38 and p-p38, and lower level of myocardial apoptosis (p < 0.05), when compared with model group.Conclusion: High-dose sufentanil reduces myocardial apoptosis and improves cardiac function, and thus can potentially be developed as a cardioprotective agent.
{"title":"Sufentanil reduces myocardial apoptosis in rats with myocardial ischemia-reperfusion injury","authors":"Jianming Yao, Xiaoyue Zhang, Xuemei Hou","doi":"10.4314/tjpr.v22i8.13","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.13","url":null,"abstract":"Purpose: To determine the effect of sufentanil on myocardial apoptosis in rats with myocardial ischemia-reperfusion injury (MIRI).Methods: Fifty Sprague Dawley rats were randomly assigned to five groups: sham, model, low-dose, moderate-dose, and high-dose. The groups, except sham, underwent ligation of the left anterior descending coronary artery to establish the MIRI model. The low, moderate, and high-dose groups received intraperitoneal injections of sufentanil at different concentrations. Cardiac function, serum LDH, creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (MDA) content were evaluated. The mRNA expression levels of apoptosis genes and protein levels of p38 and p-p38 were assessed in myocardial tissues using various methods while apoptosis was assessed by TUNEL assay.Results: Compared to sham group, the model group exhibited significant decrease in fractional shortening (FS) and ejection fraction (EF), increase in CK activity, LDH, and MDA contents, lower SOD activity. Model group also showed increase in mRNA levels of B-cell lymphoma-2 (Bcl-2) and caspase- 3, higher apoptosis, significant increase in protein levels of p38 and p-p38, and higher level of myocardial apoptosis (p < 0.05). High-dose group demonstrated significant increase in FS and EF, decrease in LDH content and CK activity, lower MDA content, higher SOD activity, decrease in mRNA levels of Bcl-2 and caspase-3, lower apoptosis, decrease in protein levels of p38 and p-p38, and lower level of myocardial apoptosis (p < 0.05), when compared with model group.Conclusion: High-dose sufentanil reduces myocardial apoptosis and improves cardiac function, and thus can potentially be developed as a cardioprotective agent.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"149 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To systematically assess the efficacy and safety of combining Euodia rutaecarpa Benth acupressure with Wendan decoction for the treatment of vertigo, thereby establishing a theoretical framework for informed clinical practice.Methods: Computer-based search was conducted in PubMed, Embase, Scopus, Web of Science, and Cochrane databases to identify randomized controlled literature pertaining to efficacy and safety of Euodia rutaecarpa Benth acupressure in combination with Wendan decoction for management of vertigo. The experimental group received an intervention of Euodia rutaecarpa Benth acupressure combined with Wendan decoction. Articles that met set inclusion and exclusion criteria were screened and evaluated for quality based on Cochrane Quality Rating Scale. Baseline data, intervention data and outcome indicators of included studies were also extracted. Meta-analysis was performed using RevMan 5.4 software.Results: The difference in symptom scores between groups was statistically significant (RR = -0.04, 95 % CI (-0.3, 0.23), p = 0.78). Meta-analysis of the outcome indicators showed heterogeneity at p < 0.0001, I2 = 91 %. I2 = 91 > 50 %. There was a statistically significant difference (p < 0.05) between groups in terms of total treatment efficiency (RR = 0.31, 95 % CI (-0.25, 0.88), p = 0.28). Heterogeneity of vertigo degree score showed p < 0.0001, I2 = 98 %. I2 = 98 % > 50 %, SMD = 2.34, 95 % CI (0.69, 3.99), p = 0.53.Conclusion: The combination of clinical Euodia rutaecarpa Upright acupressure and Wendan decoction demonstrates significant clinical effectiveness in treating vertigo as evidenced by improvement of all indicators. Moreover, this treatment approach exhibits a high level of safety.
目的:系统评价温胆汤联合朱茱萸穴压治疗眩晕的疗效和安全性，为临床实践提供理论依据。方法:计算机检索PubMed、Embase、Scopus、Web of Science、Cochrane等数据库，筛选有关刺痛联合文丹汤治疗眩晕疗效和安全性的随机对照文献。试验组患者给予温胆汤加温茱萸底穴按摩干预。根据Cochrane质量评定量表对符合纳入和排除标准的文章进行筛选和质量评价。还提取了纳入研究的基线数据、干预数据和结局指标。采用RevMan 5.4软件进行meta分析。结果:两组患者症状评分差异有统计学意义(RR = -0.04, 95% CI (-0.3, 0.23)， p = 0.78)。结果指标的荟萃分析显示p <存在异质性;0.0001, i2 = 91%。I2 = 91 >50%。差异有统计学意义(p <0.05)组间总治疗效率比较(RR = 0.31, 95% CI (-0.25, 0.88)， p = 0.28)。眩晕度评分的异质性显示p <0.0001, i2 = 98%。I2 = 98% >， SMD = 2.34, 95% CI (0.69, 3.99)， p = 0.53。结论:临床乌龙果直立指压联合温丹汤治疗眩晕临床疗效显著，各项指标均有改善。此外，这种治疗方法具有很高的安全性。
{"title":"Meta-analysis of the effectiveness of <i>Euodia rutaecarpa</i> Benth acupressure and Wendan decoction in the treatment of vertigo","authors":"Tianying Wu, Qiang Zheng, Shuxian Niu","doi":"10.4314/tjpr.v22i8.29","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.29","url":null,"abstract":"Purpose: To systematically assess the efficacy and safety of combining Euodia rutaecarpa Benth acupressure with Wendan decoction for the treatment of vertigo, thereby establishing a theoretical framework for informed clinical practice.Methods: Computer-based search was conducted in PubMed, Embase, Scopus, Web of Science, and Cochrane databases to identify randomized controlled literature pertaining to efficacy and safety of Euodia rutaecarpa Benth acupressure in combination with Wendan decoction for management of vertigo. The experimental group received an intervention of Euodia rutaecarpa Benth acupressure combined with Wendan decoction. Articles that met set inclusion and exclusion criteria were screened and evaluated for quality based on Cochrane Quality Rating Scale. Baseline data, intervention data and outcome indicators of included studies were also extracted. Meta-analysis was performed using RevMan 5.4 software.Results: The difference in symptom scores between groups was statistically significant (RR = -0.04, 95 % CI (-0.3, 0.23), p = 0.78). Meta-analysis of the outcome indicators showed heterogeneity at p < 0.0001, I2 = 91 %. I2 = 91 > 50 %. There was a statistically significant difference (p < 0.05) between groups in terms of total treatment efficiency (RR = 0.31, 95 % CI (-0.25, 0.88), p = 0.28). Heterogeneity of vertigo degree score showed p < 0.0001, I2 = 98 %. I2 = 98 % > 50 %, SMD = 2.34, 95 % CI (0.69, 3.99), p = 0.53.Conclusion: The combination of clinical Euodia rutaecarpa Upright acupressure and Wendan decoction demonstrates significant clinical effectiveness in treating vertigo as evidenced by improvement of all indicators. Moreover, this treatment approach exhibits a high level of safety.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"140 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yan Huang, Bo Du, Shiguang Zhu, Yingfeng Mu, Deqin Geng
Purpose: To determine the effect of a combination of ginkgo leaf tablets with compound carbidopa tablets on cognitive function, serum homocysteine (Hcy), malondialdehyde (MDA) and neuron-specific enolase (NSE) levels in patients with Parkinson's disease (PD).Methods: A total of eighty (80) PD patients admitted to The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China between December 2020 and December 2022 were randomly divided into two groups: Western medicine group (n = 40, using compound carbidopa tablets alone) and combination group (n = 40, using ginkgo leaf tablets combined with compound carbidopa tablets), and orally treated for 3 months. Mini-mental state examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess cognitive function before and after treatment. High-performance liquid chromatography was used to determine serum Hcy levels, while enzyme-linked immunosorbent assay (ELISA) was used to evaluate serum MDA and NSE levels. Adverse reactions were also recorded during treatment.Results: Total response rate following treatment in combination group was significantly higher than in Western medicine group (95.00 vs 80.00 %, p < 0.05). After treatment, MMSE and MoCA scores in combination group were significantly higher (p < 0.05) than those in Western medicine group, while serum Hcy, MDA and NSE levels in combination group were significantly lower than those in Western medicine group (p < 0.05). During treatment, there was no significant difference in incidence of adverse reactions between the two groups (p > 0.05).Conclusion: Ginkgo leaf tablets in combination with carbidopa significantly improve cognitive functions associated with PD with high safety, when compared to carbidopa tablets alone. However, further clinical trials are commended to validate these findings.
目的:探讨银杏叶片联合复方卡比多巴片对帕金森病(PD)患者认知功能、血清同型半胱氨酸(Hcy)、丙二醛(MDA)和神经元特异性烯醇化酶(NSE)水平的影响。方法:选取2020年12月至2022年12月在中国徐州医科大学附属医院住院的80例PD患者，随机分为西药组(n = 40，单用复方卡比多巴片)和联用组(n = 40，银杏叶片联合复方卡比多巴片)，口服治疗3个月。治疗前后分别采用简易精神状态检查(MMSE)和蒙特利尔认知评估(MoCA)评估认知功能。采用高效液相色谱法测定血清Hcy水平，酶联免疫吸附试验(ELISA)测定血清MDA和NSE水平。同时记录治疗过程中的不良反应。结果:联合组治疗后总有效率显著高于西药组(95.00% vs 80.00 %， p <0.05)。治疗后，联合组患者MMSE、MoCA评分均显著高于对照组(p <联合用药组血清Hcy、MDA、NSE水平显著低于西药组(p <0.05)。治疗期间，两组患者不良反应发生率比较，差异无统计学意义(p >0.05)。结论:银杏叶片联合卡比多巴与单用卡比多巴相比，可显著改善PD患者认知功能，且安全性高。然而，建议进一步的临床试验来验证这些发现。
{"title":"Effect of ginkgo leaf tablets combined with compound carbidopa on patients with Parkinson’s disease","authors":"Yan Huang, Bo Du, Shiguang Zhu, Yingfeng Mu, Deqin Geng","doi":"10.4314/tjpr.v22i8.19","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.19","url":null,"abstract":"Purpose: To determine the effect of a combination of ginkgo leaf tablets with compound carbidopa tablets on cognitive function, serum homocysteine (Hcy), malondialdehyde (MDA) and neuron-specific enolase (NSE) levels in patients with Parkinson's disease (PD).Methods: A total of eighty (80) PD patients admitted to The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China between December 2020 and December 2022 were randomly divided into two groups: Western medicine group (n = 40, using compound carbidopa tablets alone) and combination group (n = 40, using ginkgo leaf tablets combined with compound carbidopa tablets), and orally treated for 3 months. Mini-mental state examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess cognitive function before and after treatment. High-performance liquid chromatography was used to determine serum Hcy levels, while enzyme-linked immunosorbent assay (ELISA) was used to evaluate serum MDA and NSE levels. Adverse reactions were also recorded during treatment.Results: Total response rate following treatment in combination group was significantly higher than in Western medicine group (95.00 vs 80.00 %, p < 0.05). After treatment, MMSE and MoCA scores in combination group were significantly higher (p < 0.05) than those in Western medicine group, while serum Hcy, MDA and NSE levels in combination group were significantly lower than those in Western medicine group (p < 0.05). During treatment, there was no significant difference in incidence of adverse reactions between the two groups (p > 0.05).Conclusion: Ginkgo leaf tablets in combination with carbidopa significantly improve cognitive functions associated with PD with high safety, when compared to carbidopa tablets alone. However, further clinical trials are commended to validate these findings.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135484830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shutian Shi, Lei Zhen, Mei Wang, Chunmei Wang, Hui Ai, Bin Que, Shaoping Nie
Purpose: To investigate the efficacy and safety of unfractionated heparin (UFH) anticoagulant administered upstream in the ambulance or emergency room during primary percutaneous coronary intervention (pPCI) for patients with acute ST-segment elevation myocardial infarction (STEMI).Methods: The study included STEMI patients who received either early UFH subcutaneously (SC) (n = 163) or intraoperative UFH (SC) during pPCI (n = 476) between January 2017 to August 2018. Baseline characteristics, infarct-related artery (IRA) status, and procedural characteristics were analyzed. The primary endpoint was thrombolysis in myocardial infarction (TIMI) flow grade 2 - 3 before intervention. The secondary endpoints were time from first medical contact to guidewire passage, postoperative TIMI 3 flow grade, acute stent thrombosis, and in-hospital bleeding events.Results: Baseline characteristics were similar between the groups, with no significant difference in IRA location. Both groups underwent coronary angiography, with most patients receiving pPCI. The primary endpoint occurred in 18.1 % of patients in intraoperative UFH group and 27.6 % in the early UFH group, with a significant difference between the groups (p < 0.05). There was no significant difference in postoperative TIMI 3 flow grade or acute stent thrombosis, but bleeding events (BARC 2-5) were similar between groups (1.1 % in intraoperative group and 1.8 % in early UFH group, p > 0.05)Conclusion: Early upstream administration of UFH anticoagulation in STEMI patients improves coronary artery potency before pPCI, and early use of fixed-dose UFH is safe and does not increase major bleeding complications.
{"title":"Effects of early application of heparin on coronary blood flow during primary percutaneous coronary intervention","authors":"Shutian Shi, Lei Zhen, Mei Wang, Chunmei Wang, Hui Ai, Bin Que, Shaoping Nie","doi":"10.4314/tjpr.v22i8.21","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.21","url":null,"abstract":"Purpose: To investigate the efficacy and safety of unfractionated heparin (UFH) anticoagulant administered upstream in the ambulance or emergency room during primary percutaneous coronary intervention (pPCI) for patients with acute ST-segment elevation myocardial infarction (STEMI).Methods: The study included STEMI patients who received either early UFH subcutaneously (SC) (n = 163) or intraoperative UFH (SC) during pPCI (n = 476) between January 2017 to August 2018. Baseline characteristics, infarct-related artery (IRA) status, and procedural characteristics were analyzed. The primary endpoint was thrombolysis in myocardial infarction (TIMI) flow grade 2 - 3 before intervention. The secondary endpoints were time from first medical contact to guidewire passage, postoperative TIMI 3 flow grade, acute stent thrombosis, and in-hospital bleeding events.Results: Baseline characteristics were similar between the groups, with no significant difference in IRA location. Both groups underwent coronary angiography, with most patients receiving pPCI. The primary endpoint occurred in 18.1 % of patients in intraoperative UFH group and 27.6 % in the early UFH group, with a significant difference between the groups (p < 0.05). There was no significant difference in postoperative TIMI 3 flow grade or acute stent thrombosis, but bleeding events (BARC 2-5) were similar between groups (1.1 % in intraoperative group and 1.8 % in early UFH group, p > 0.05)Conclusion: Early upstream administration of UFH anticoagulation in STEMI patients improves coronary artery potency before pPCI, and early use of fixed-dose UFH is safe and does not increase major bleeding complications.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To investigate the use of enteral nutrition (EN) and factors influencing feeding intolerance (FI) in severely ill patients in intensive care unit (ICU).Methods: Retrospective data collection was performed on records of 247 severely ill patients admitted to ICU of the West China Hospital, Chengdu, China between January 2020 and December 2022. Data were divided into two groups: FI group (n = 107) and non-FI group (n = 140). Influencing factors of FI were analyzed by univariate and multivariate analysis, and the use of EN was analyzed.Results: Defined daily doses (DDDs) of enteral nutrition emulsion TPF-T (Ruineng), enteral nutrition suspension (Baipuli) and enteral nutrition emulsion TPF (Ruixian) were most prevalent. The DDDs of enteral nutrition suspension (Nengquanli 1.5) increased, while that of Nengquanli 1.0 decreased. Univariate analysis showed significant differences between FI and non-FI groups in start time of EN, addition of dietary fiber, Acute Physiology and Chronic Health Evaluation (APACHE) II score, use of sedatives, types of antibiotics used, use of vasoactive drugs and oral potassium preparation, mechanical ventilation and hypoalbuminemia (p < 0.05). Multivariate analysis showed that addition of dietary fiber, APACHE II score ≥ 20 points, sedatives use, types of antibiotics used ≥ 2, oral potassium preparation and hypoalbuminemia were independent risk factors of FI.Conclusion: Use of EN in ICU is consistent. Factors that influence FI in critically ill patients include dietary fiber, APACHE II score, use of sedatives, use of antibiotics, use oral potassium preparations and hypoalbuminemia. Knowledge of these risk factors and timely measures are of great significance in avoiding FI in ICU.
{"title":"Use of enteral nutrition and factors influencing feeding intolerance in severely ill patients in the intensive care unit","authors":"Fen Tang, Pai Liu, Chunyan Wang","doi":"10.4314/tjpr.v22i8.22","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.22","url":null,"abstract":"Purpose: To investigate the use of enteral nutrition (EN) and factors influencing feeding intolerance (FI) in severely ill patients in intensive care unit (ICU).Methods: Retrospective data collection was performed on records of 247 severely ill patients admitted to ICU of the West China Hospital, Chengdu, China between January 2020 and December 2022. Data were divided into two groups: FI group (n = 107) and non-FI group (n = 140). Influencing factors of FI were analyzed by univariate and multivariate analysis, and the use of EN was analyzed.Results: Defined daily doses (DDDs) of enteral nutrition emulsion TPF-T (Ruineng), enteral nutrition suspension (Baipuli) and enteral nutrition emulsion TPF (Ruixian) were most prevalent. The DDDs of enteral nutrition suspension (Nengquanli 1.5) increased, while that of Nengquanli 1.0 decreased. Univariate analysis showed significant differences between FI and non-FI groups in start time of EN, addition of dietary fiber, Acute Physiology and Chronic Health Evaluation (APACHE) II score, use of sedatives, types of antibiotics used, use of vasoactive drugs and oral potassium preparation, mechanical ventilation and hypoalbuminemia (p < 0.05). Multivariate analysis showed that addition of dietary fiber, APACHE II score ≥ 20 points, sedatives use, types of antibiotics used ≥ 2, oral potassium preparation and hypoalbuminemia were independent risk factors of FI.Conclusion: Use of EN in ICU is consistent. Factors that influence FI in critically ill patients include dietary fiber, APACHE II score, use of sedatives, use of antibiotics, use oral potassium preparations and hypoalbuminemia. Knowledge of these risk factors and timely measures are of great significance in avoiding FI in ICU.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To examine the effect of abietic acid (AA) in the treatment of acute pancreatitis (AP) in mice.Methods: C57BL/6J mice were randomly assigned to 4 groups: sham, AP, AP + 20 mg/kg AA, and AP + 40 mg/kg AA groups. To induce AP mouse model, the mice received intraperitoneal (IP) injections of cerulein. The extent of pancreatic tissue damage was evaluated by histological examination. Serum ALT, lipase, and amylase levels were determined by commercial kits while TUNEL assay was used to assess the apoptosis of pancreatic cells. The contents of Bax, Caspase-3, Bcl-2, p-ERK/ERK, p-JNK/JNK, and p-P38/P38 in pancreatic tissues were evaluated by western blot while the contents of IL-6, TNF-α, IL-1β, nitrite, MDA, and GSH in the tissues were evaluated by enzyme-linked immunosorbent assay (ELISA) kits.Results: AA relieved pancreatic damage and reduced ALT, lipase, and amylase levels in ceruleintreated AP mouse (p < 0.001). AA repressed apoptosis of pancreatic cells in cerulein-induced AP mouse, and inhibited oxidative stress and inflammatory response in the mice by reducing IL-6, TNF-α, IL-1β, nitrite, and MDA contents; it also enhanced the levels of GSH in the tissues (p < 0.001). In addition, AA inhibited MAPK pathway activity in the mice (p < 0.001).Conclusion: AA ameliorates pancreatic damage, pancreatic cell apoptosis, oxidative stress, and inflammation in cerulein-induced AP mouse by inhibiting MAPK pathway. This study offers a new potential drug for the management of AP and expands the relevant molecular regulatory mechanisms.
{"title":"Abietic acid ameliorates pancreatic injury in acute pancreatitis by modulating MAPK pathway","authors":"Hailin Ye, Jun Wang, Jiaodan Mao, Debiao Pan","doi":"10.4314/tjpr.v22i8.7","DOIUrl":"https://doi.org/10.4314/tjpr.v22i8.7","url":null,"abstract":"Purpose: To examine the effect of abietic acid (AA) in the treatment of acute pancreatitis (AP) in mice.Methods: C57BL/6J mice were randomly assigned to 4 groups: sham, AP, AP + 20 mg/kg AA, and AP + 40 mg/kg AA groups. To induce AP mouse model, the mice received intraperitoneal (IP) injections of cerulein. The extent of pancreatic tissue damage was evaluated by histological examination. Serum ALT, lipase, and amylase levels were determined by commercial kits while TUNEL assay was used to assess the apoptosis of pancreatic cells. The contents of Bax, Caspase-3, Bcl-2, p-ERK/ERK, p-JNK/JNK, and p-P38/P38 in pancreatic tissues were evaluated by western blot while the contents of IL-6, TNF-α, IL-1β, nitrite, MDA, and GSH in the tissues were evaluated by enzyme-linked immunosorbent assay (ELISA) kits.Results: AA relieved pancreatic damage and reduced ALT, lipase, and amylase levels in ceruleintreated AP mouse (p < 0.001). AA repressed apoptosis of pancreatic cells in cerulein-induced AP mouse, and inhibited oxidative stress and inflammatory response in the mice by reducing IL-6, TNF-α, IL-1β, nitrite, and MDA contents; it also enhanced the levels of GSH in the tissues (p < 0.001). In addition, AA inhibited MAPK pathway activity in the mice (p < 0.001).Conclusion: AA ameliorates pancreatic damage, pancreatic cell apoptosis, oxidative stress, and inflammation in cerulein-induced AP mouse by inhibiting MAPK pathway. This study offers a new potential drug for the management of AP and expands the relevant molecular regulatory mechanisms.","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135485725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：